Collegium Pharmaceutical, Inc. COLL Belbuca — Product revenues, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net?
- Collegium Pharmaceutical, Inc. (COLL) reported belbuca — product revenues, net of $52.65M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net changed year-over-year?
- Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net increased by 1.9% year-over-year, from $51.66M to $52.65M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net has grown at a 20.6% compound annual growth rate (CAGR), from $126.46M to $221.65M.
- What does belbuca — product revenues, net mean?
- Represents the total net revenue generated from the sale of the Belbuca product line after accounting for returns, allowances, and rebates. This metric is a primary indicator of the product's market adoption and commercial performance within the specialty pharmaceutical portfolio.